Invex Therapeutics (ASX:IXC) Tax Rate %: 0.00% (As of Dec. 2025)


What is Invex Therapeutics Tax Rate %?

Invex Therapeutics ASX:IXC Tax Rate % is 0.00% as of Dec. 2025. The stock has 1 warning sign investors should review.

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Invex Therapeutics's Tax Expense for the six months ended in Dec. 2025 was A$0.00 Mil. Invex Therapeutics's Pre-Tax Income for the six months ended in Dec. 2025 was A$-0.72 Mil. Therefore, Invex Therapeutics's Tax Rate % for the quarter that ended in Dec. 2025 was 0.00%.

Invex Therapeutics Tax Rate % Related Terms

Invex Therapeutics Tax Rate % Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Tax Rate % Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Tax Rate %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Invex Therapeutics Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Invex Therapeutics's Tax Rate % for the fiscal year that ended in Jun. 2025 is calculated as

Tax Rate %=Tax Expense (A: Jun. 2025 )/Pre-Tax Income (A: Jun. 2025 )
=0/-0.477
=0.00 %

Invex Therapeutics's Tax Rate % for the quarter that ended in Dec. 2025 is calculated as

Tax Rate %=Tax Expense (Q: Dec. 2025 )/Pre-Tax Income (Q: Dec. 2025 )
=0/-0.716
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Rate % →
What does a Tax Rate % of 0.00% mean?
Invex Therapeutics (ASX:IXC) has a Tax Rate % of 0.00% as of Dec. 2025.
Is Invex Therapeutics' Tax Rate % too high?
Invex Therapeutics' current Tax Rate % is 0.00%.
How does Invex Therapeutics' Tax Rate % compare to VRTX and REGN?
Invex Therapeutics' Tax Rate % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Rate % for a Biotechnology company?
A good Tax Rate % depends on the Biotechnology industry context. However, Tax Rate % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Rate % mean?
A high Tax Rate % can signal that a stock is expensive relative to its fundamentals. Invex Therapeutics's current Tax Rate % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Tax Rate % of 0.00%. The current Tax Rate % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Rate % calculated?
Tax Rate % is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Tax Rate % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.